Impaired CD4<sup>+</sup> T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37118516.
- Also identified by DOI 10.1038/s43587-022-00343-4 and PMC identifier 10154196.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Whether age-associated defects in T cells impact the immunogenicity and reactogenicity of mRNA vaccines remains unclear. Using a vaccinated cohort (n = 216), we demonstrated that older adults (aged ≥65 years) had fewer vaccine-induced spike-specific CD4<sup>+</sup> T cells including CXCR3<sup>+</sup> circulating follicular helper T cells and the T<sub>H</sub>1 subset of helper T cells after the first dose, which correlated with their lower peak IgG levels and fewer systemic adverse effects after the second dose, compared with younger adults. Moreover, spike-specific T<sub>H</sub>1 cells in older adults expressed higher levels of programmed cell death protein 1, a negative regulator of T cell activation, which was associated with low spike-specific CD8<sup>+</sup> T cell responses. Thus, an inefficient CD4<sup>+</sup> T cell response after the first dose may reduce the production of helper T cytokines, even after the second dose, thereby lowering humoral and cellular immunity and reducing systemic reactogenicity. Therefore, enhancing CD4<sup>+</sup> T cell response following the first dose is key to improving vaccine efficacy in older adults.
Medical subject headings
- COVID-19 Vaccines
- COVID-19